Literature DB >> 26216671

Commentary to: Cost of poor adherence to anti-hypertensive therapy in five European countries.

Afschin Gandjour1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26216671     DOI： 10.1007/s10198-015-0713-x

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN： 1618-7598


× No keyword cloud information.
  3 in total

1.  Cost of poor adherence to anti-hypertensive therapy in five European countries.

Authors:  F S Mennini; A Marcellusi; J M Graf von der Schulenburg; A Gray; P Levy; P Sciattella; M Soro; G Staffiero; J Zeidler; A Maggioni; R E Schmieder
Journal:  Eur J Health Econ       Date:  2014-01-05

2.  A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness.

Authors:  Afschin Gandjour; Stephanie Stock
Journal:  Health Policy       Date:  2007-03-01       Impact factor: 2.980

3.  The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis.

Authors:  Alan A Montgomery; Tom Fahey; Yoav Ben-Shlomo; James Harding
Journal:  J Hypertens       Date:  2003-09       Impact factor: 4.844
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.